{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:00Z","timestamp":1793502660789,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["BMBF O1KD 1906"],"award-info":[{"award-number":["BMBF O1KD 1906"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00432-023-05137-8","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T08:02:23Z","timestamp":1689753743000},"page":"12897-12902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials"],"prefix":"10.1007","volume":"149","author":[{"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Zapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Allgaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6tz","family":"Gelbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Pryss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"5137_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/PPA.S345906","volume":"16","author":"D Auclair","year":"2022","unstructured":"Auclair D et al (2022) Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adherence 16:573","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"5137_CR2","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, Lebioda A (2021) Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk 21(2):e160\u2013e175. https:\/\/doi.org\/10.1016\/j.clml.2020.10.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5137_CR3","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA et al (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4(9):e431\u2013e442","journal-title":"Lancet Haematol"},{"issue":"2","key":"5137_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K et al (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22(2):417\u2013426","journal-title":"Support Care Cancer"},{"key":"5137_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdx757","volume":"29","author":"K Jordan","year":"2018","unstructured":"Jordan K, Aapro M, Kaasa S et al (2018) ESMO position paper on supportive and palliative care. Ann Oncol 29:36\u201343","journal-title":"Ann Oncol"},{"issue":"29","key":"5137_CR6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279","journal-title":"J Clin Oncol"},{"key":"5137_CR7","doi-asserted-by":"crossref","unstructured":"Mohyuddin GR et al (2022) A patient perspective on cure in multiple myeloma: a survey of over 1,500 patients, pp 8046\u20138046.","DOI":"10.1200\/JCO.2022.40.16_suppl.8046"},{"issue":"4","key":"5137_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F et al (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89(4):311\u2013319","journal-title":"Eur J Haematol"},{"issue":"15","key":"5137_CR9","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","volume":"124","author":"C Pawlyn","year":"2014","unstructured":"Pawlyn C et al (2014) Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 124(15):2467\u20132468","journal-title":"Blood"},{"key":"5137_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387:132\u2013147","journal-title":"N Engl J Med"},{"key":"5137_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/PPA.S104259","volume":"10","author":"JA Sacrist\u00e1n","year":"2016","unstructured":"Sacrist\u00e1n JA et al (2016) Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence 10:631","journal-title":"Patient Prefer Adherence"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05137-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:09:17Z","timestamp":1697688557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":11,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5137"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05137-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2975755\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KJ reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda) and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm and Voluntis HE reports personal fees from:\u2008Janssen,Celgene\/BMS, Amgen, GSK, Sanofi: Consultancy, Honoraria, Research, NW:\u2008Sanofi: Honoraria. AF: fees for advisory board membership from GSK, speaker training BMS, LR personal fees from:\u2008Janssen,Celgene\/BMS, Amgen, GSK, Sanofi, Pfizer: Consultancy, Honoraria. The remaining authors report no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of W\u00fcrzburg (AZ 270\/20).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Only patients who were able to give informed consent were included.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All included patients gave their consent for publication of the collected data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}